

Lanfranco Pellesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9162336/publications.pdf>

Version: 2024-02-01

29
papers

574
citations

687363
13
h-index

610901
24
g-index

31
all docs

31
docs citations

31
times ranked

723
citing authors

#	ARTICLE	IF	CITATIONS
1	PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation. Cephalalgia, 2022, 42, 687-695.	3.9	8
2	Clinical Evidence of Cannabinoids in Migraine: A Narrative Review. Journal of Clinical Medicine, 2022, 11, 1479.	2.4	7
3	Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study. Frontiers in Neurology, 2022, 13, 871176.	2.4	6
4	A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. Expert Opinion on Drug Safety, 2021, 20, 467-474.	2.4	7
5	Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches. JAMA Network Open, 2021, 4, e2118543.	5.9	38
6	Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review. Drug, Healthcare and Patient Safety, 2021, Volume 13, 233-240.	2.5	3
7	Nummular headache: a gender-oriented perspective on a case series from the RegisRare Network. Neurological Sciences, 2020, 41, 583-589.	1.9	7
8	<p>Reducing Episodic Cluster Headaches: Focus on Galcanezumab</p>. Journal of Pain Research, 2020, Volume 13, 1591-1599.	2.0	2
9	Dual Therapy With Anti-€CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?. Headache, 2020, 60, 1056-1065.	3.9	58
10	Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia, 2020, 40, 1212-1223.	3.9	30
11	Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study. Cephalalgia, 2020, 40, 1070-1078.	3.9	6
12	Nabilone administration in refractory chronic diarrhea: a case series. BMC Gastroenterology, 2019, 19, 105.	2.0	13
13	Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-€overuse headache. BMC Neurology, 2019, 19, 239.	1.8	3
14	Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 189-198.	3.3	19
15	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. Journal of Headache and Pain, 2019, 20, 15.	6.0	7
16	SAT0285-€EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS. , 2019, , .		0
17	Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. Pharmacological Research, 2018, 133, 65-76.	7.1	30
18	Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. Frontiers in Neurology, 2018, 9, .	2.4	0

#	ARTICLE	IF	CITATIONS
19	Migraine and cluster headache – the common link. Journal of Headache and Pain, 2018, 19, 89.	6.0	44
20	Rare primary headaches in Italian tertiary Headache Centres: Three year nationwide retrospective data from the RegistRare Network. Cephalalgia, 2018, 38, 1429-1441.	3.9	9
21	Response to: “Drugs for treatment for alcohol use disorders expose to interactions with others” for little benefit if any. Pharmacological Research, 2018, 134, 220.	7.1	0
22	Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH) – a pilot study. European Journal of Clinical Pharmacology, 2018, 74, 1427-1436.	1.9	27
23	Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clinical Pharmacology in Drug Development, 2017, 6, 534-547.	1.6	56
24	Triptans and CGRP blockade – impact on the cranial vasculature. Journal of Headache and Pain, 2017, 18, 103.	6.0	50
25	Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. Journal of Headache and Pain, 2017, 18, 71.	6.0	34
26	Quality indicators in headache care: an implementation study in six Italian specialist-care centres. Journal of Headache and Pain, 2017, 18, 55.	6.0	19
27	Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. Frontiers in Neurology, 2017, 8, 586.	2.4	42
28	Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. Journal of Headache and Pain, 2016, 17, 48.	6.0	49
29	Greater Occipital Nerve Block with Local Anesthetics and Corticosteroids in Treatment-Resistant Chronic Migraine. Headache Medicine, 0, , 160-167.	0.2	0